KYKOF - Syndax: SNDX-6352's Pivotal Trial Initiation In 2021 And $176M In Cash
- Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD.
- Syndax has a pipeline of 3 therapeutics (SNDX-5613, SNDX-6352, Entinostat) with 2 still-progressing through clinical trials and one delayed. Syndax has opened the possibility of using cash for therapeutic acquisitions.
- Syndax Pharmaceuticals has reset after poor Phase 3 results for Entinostat with cash built up to $176M and analysts now expecting that by Dec 2024, revenue will return to promising levels ($93M).
- Syndax's next key update will be in late Dec / early 1Q 2020 on the update of pivotal trial initiation for SNDX-6352.
- In summary, the author project Syndax Pharmaceuticals as a risky "buy" at a 2-year price target of $41 (+70% upside).
For further details see:
Syndax: SNDX-6352's Pivotal Trial Initiation In 2021 And $176M In Cash